ClinicalTrials.gg

Program

ensifentrine

Also written as “Ensifentrine”, “RPL554” and “Ensifentrine 3 mg”.

Its studies are mostly in Pulmonary Disease, Chronic Obstructive · Cystic Fibrosis · Asthma, led by 2 companies.

Furthest: phase 3, since Aug 19, 202017 company-led studies, 2 open or runningAcquisition: Merck acquired Verona Pharma, Oct 2025Next primary completion: Mar 1, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Merck152 open or runningphase 3since Aug 19, 2020Nov 30, 2014Mar 1, 2027phase 2 · NCT05270525
Nuance Pharma (shanghai)20 open or runningphase 3since Feb 14, 2023Feb 14, 2023none ahead
  • Named in Merck’s own pipeline as ensifentrine (+) glycopyrrolate (MK-5884A), phase 2, as of Nov 2, 2026 (source).

Also a collaborator on its studies: Laboratory Corporation of America and Iqvia Pty.

How these companies relate

From the companies’ own releases and filings, each linked; the registry does not say.

  • LicenseNuance Pharma licensed it from Verona Pharma, for Greater China (mainland China, Taiwan, Hong Kong and Macau).Agreed Jun 9, 2021 · Source: Verona Pharma (8-K), Jun 11, 2021
  • AcquisitionMerck acquired Verona Pharma, and with it ensifentrine (Ohtuvayre).Completed Oct 7, 2025 · Source: Merck, Oct 7, 2025

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). A diamond marks a license, acquisition or co-development, from the companies’ own releases and filings. Dates ahead are the sponsors’ estimates.

Before these, 3 studies since Nov 30, 2014.

  1. Sep 21, 2016Phase 2 study in Cystic FibrosisMerck · NCT02919995 · 10 enrolled · United Kingdom
  2. Jan 3, 2017Phase 2 study in Chronic Obstructive Pulmonary Disease ModerateMerck · NCT03028142 · 30 enrolled
  3. Feb 7, 2018Phase 2 study in Pulmonary Disease, Chronic ObstructiveMerck · NCT03443414 · 405 enrolled · Bulgaria, Czechia, Germany and more
  4. Sep 7, 2018Phase 2 study in Pulmonary Disease, Chronic ObstructiveMerck · NCT03673670 · 79 enrolled · United States, United Kingdom
  5. Jun 20, 2019Phase 2 study in Pulmonary Disease, Chronic ObstructiveMerck · NCT04091360 · 40 enrolled · United Kingdom
  6. Aug 19, 2020Phase 3 study in Pulmonary Disease, Chronic ObstructiveMerck · NCT04535986 · 763 enrolled · United States, Bulgaria, Czechia and more
  7. Sep 1, 2020Phase 3 study in Pulmonary Disease, Chronic ObstructiveMerck · NCT04542057 · 790 enrolled · United States, Belgium, Bulgaria and more
  8. Jun 9, 2021Nuance Pharma licensed it from Verona PharmaLicenseGreater China (mainland China, Taiwan, Hong Kong and Macau) · agreed · Verona Pharma (8-K)
  9. Feb 8, 2022Phase 2 study in Lung DiseasesMerck · NCT05270525 · 70 enrolled · United States
  10. Feb 14, 2023Nuance Pharma (shanghai)'s first study: phase 1 study in Pulmonary Disease, Chronic ObstructiveNew to Nuance Pharma (shanghai)Nuance Pharma (shanghai) · NCT05758428 · 28 enrolled · China
  11. Feb 14, 2023Phase 3 study in Pulmonary Disease, Chronic ObstructiveNuance Pharma (shanghai) · NCT05743075 · 526 enrolled · China
  12. Jun 10, 2024Phase 3 study in Pulmonary Disease, Chronic ObstructiveMerck · NCT06460493 · 20 enrolled · United States
  13. Jun 3, 2025Phase 2 study in Pulmonary Disease, Chronic ObstructiveMerck · NCT07016412 · 497 enrolled · United States
  14. Aug 11, 2025Phase 2 study in Pulmonary Disease, Chronic ObstructiveMerck · NCT07132983 · 33 enrolled · United States
  15. Oct 7, 2025Merck acquired Verona PharmaAcquisitionWith it ensifentrine (Ohtuvayre) · completed · Merck
  16. Sep 30, 2026Phase 3 study in Pulmonary Disease, Chronic ObstructiveMerck · NCT07874815 · 2,136 planned · United States

Ahead

  1. Mar 1, 2027Primary completion: phase 2 study in Lung DiseasesMerck · NCT05270525
  2. Apr 29, 2029Primary completion: phase 3 study in Pulmonary Disease, Chronic ObstructiveMerck · NCT07874815

TargetBeta

“An inhaled inhibitor of the phosphodiesterase (PDE) types 3 (PDE3) and 4 (PDE4), with potential anti-inflammatory and bronchodilator activities. Upon administration, ensifentrine targets, binds to and inhibits PDE3 and PDE4, which leads to an increase of both intracellular levels of cyclic-3',5'-…”NCIt, read by Claude
“An inhaled inhibitor of the phosphodiesterase (PDE) types 3 (PDE3) and 4 (PDE4), ”NCIt, by rule
“Phosphodiesterase 4 inhibitor; Phosphodiesterase 3 inhibitor”ChEMBL 37, by rule

Studies

All 17 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07874815Pulmonary Disease, Chronic Obstructive · United States3RecruitingMerckApr 29, 20292,136
NCT07132983Pulmonary Disease, Chronic Obstructive · United States2CompletedMerckNov 28, 202533
NCT07016412Pulmonary Disease, Chronic Obstructive · United States2CompletedMerckAug 17, 2026497
NCT06460493Pulmonary Disease, Chronic Obstructive · United States3CompletedMerckNov 26, 202420
NCT05758428Pulmonary Disease, Chronic Obstructive · China1CompletedNuance Pharma (shanghai)Apr 18, 202328
NCT05743075Pulmonary Disease, Chronic Obstructive · China3CompletedNuance Pharma (shanghai)Dec 6, 2024526
NCT05270525Lung Diseases · United States2Active, not recruitingMerckMar 1, 202770
NCT04542057Pulmonary Disease, Chronic Obstructive · United States, Belgium, Bulgaria and more3CompletedMerckMay 3, 2022790
NCT04535986Pulmonary Disease, Chronic Obstructive · United States, Bulgaria, Czechia and more3CompletedMerckSep 12, 2022763
NCT04091360Pulmonary Disease, Chronic Obstructive · United Kingdom2CompletedMerckDec 10, 202040
NCT03673670Pulmonary Disease, Chronic Obstructive · United States, United Kingdom2CompletedMerckNov 13, 201879
NCT03443414Pulmonary Disease, Chronic Obstructive · Bulgaria, Czechia, Germany and more2CompletedMerckJan 23, 2018405
NCT03028142Chronic Obstructive Pulmonary Disease Moderate2CompletedMerckAug 201730
NCT02919995Cystic Fibrosis · United Kingdom2CompletedMerckNov 3, 201710
NCT02542254Pulmonary Disease, Chronic Obstructive · United Kingdom2CompletedMerckDec 201536
NCT02427165Asthma · Sweden, United Kingdom2CompletedMerckNov 201529
NCT02307162Pulmonary Disease, Chronic Obstructive · United Kingdom1CompletedMerckJul 2015112

How it is read

Names in the registry

  • “Ensifentrine”, 7 entries
  • “RPL554”, 4 entries
  • “Ensifentrine 3 mg”, 2 entries
  • “Ensifentrine 1.5 mg”, 1 entry
  • “Ensifentrine 3 mg (marketed formulation)”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.